Equities analysts predict that Aurora Cannabis Inc. (NYSE:ACB) will announce earnings per share (EPS) of ($0.17) for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Aurora Cannabis’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.20). Aurora Cannabis posted earnings of ($0.28) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 39.3%. The company is expected to report its next earnings report on Thursday, February 10th.
According to Zacks, analysts expect that Aurora Cannabis will report full-year earnings of ($0.59) per share for the current financial year, with EPS estimates ranging from ($0.69) to ($0.47). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.40) per share, with EPS estimates ranging from ($0.51) to ($0.31). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Aurora Cannabis.
Aurora Cannabis (NYSE:ACB) last posted its quarterly earnings data on Tuesday, November 9th. The company reported ($0.09) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.09. Aurora Cannabis had a negative return on equity of 9.09% and a negative net margin of 252.40%. The firm had revenue of $47.74 million for the quarter, compared to analysts’ expectations of $47.84 million.
Several equities research analysts have weighed in on the company. Jefferies Financial Group reiterated a “hold” rating on shares of Aurora Cannabis in a report on Friday, October 1st. Needham & Company LLC reiterated a “sell” rating on shares of Aurora Cannabis in a research note on Tuesday, September 28th. MKM Partners raised Aurora Cannabis from a “sell” rating to a “neutral” rating and increased their price objective for the company from $6.00 to $7.00 in a report on Tuesday, September 28th. cut their price objective on Aurora Cannabis from C$6.50 to C$6.00 and set a “sell” rating on the stock in a report on Thursday, November 11th. Finally, Zacks Investment Research lowered Aurora Cannabis from a “hold” rating to a “sell” rating in a report on Tuesday, January 11th. Five analysts have rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $7.08.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACB. Advisory Services Network LLC purchased a new position in shares of Aurora Cannabis during the 2nd quarter worth $35,000. Citigroup Inc. increased its holdings in Aurora Cannabis by 684.4% in the 3rd quarter. Citigroup Inc. now owns 6,048 shares of the company’s stock valued at $42,000 after purchasing an additional 5,277 shares in the last quarter. PFG Advisors acquired a new stake in shares of Aurora Cannabis during the fourth quarter valued at about $56,000. Spire Wealth Management grew its stake in shares of Aurora Cannabis by 73.0% during the fourth quarter. Spire Wealth Management now owns 10,384 shares of the company’s stock valued at $56,000 after acquiring an additional 4,382 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aurora Cannabis during the third quarter valued at about $77,000. Institutional investors own 17.24% of the company’s stock.
NYSE:ACB traded down $0.29 during trading hours on Friday, reaching $4.46. The stock had a trading volume of 6,429,615 shares, compared to its average volume of 5,939,661. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.13 and a current ratio of 5.42. Aurora Cannabis has a 52 week low of $4.41 and a 52 week high of $18.98. The company has a 50 day moving average price of $6.04 and a two-hundred day moving average price of $6.73. The stock has a market capitalization of $884.77 million, a PE ratio of -1.71 and a beta of 2.92.
About Aurora Cannabis
Aurora Cannabis, Inc engages in the production, distribution and sale of cannabis products. It also produces and sells indoor cultivation systems and hemp related food products. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.
Featured Article: What is insider trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Aurora Cannabis, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aurora Cannabis wasn’t on the list.
While Aurora Cannabis currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.